Robert A. Medv

Robert A. Medv

Geen lopende functies

58 jaar
Health Technology
Consumer Services
Commercial Services

Profiel

Robert A.
Medv
worked as a Principal at Johnson & Johnson from 1998 to 2003 and as a Principal at Abbott India Ltd.
from 1996 to 1998.
He was the Chief Medical Officer at Metaphore Pharmaceuticals, Inc. from 2003 to 2006 and the Chief Medical & Regulatory Officer at NeurAxon, Inc. from 2006 to 2011.
He also worked as the Vice President-Science, Research & Development at Lifetree Clinical Research LC in 2006.
From 2011 to 2014, he was the Chief Medical Officer & Senior Vice President at Nektar Therapeutics and later the Chief Medical Officer at CARA Therapeutics, Inc. in 2014.
Dr. Medv received his undergraduate degree from The Pennsylvania State University and his doctorate from Sidney Kimmel Medical College.

Eerdere bekende functies van Robert A. Medv

BedrijvenFunctieEinde
CARA THERAPEUTICS, INC. Hoofd Techniek/Wetenschap/O&O 01-10-2014
NEKTAR THERAPEUTICS Hoofd Techniek/Wetenschap/O&O 16-05-2014
Hoofd Techniek/Wetenschap/O&O -
Hoofd Techniek/Wetenschap/O&O 01-11-2006
Hoofd Techniek/Wetenschap/O&O 05-06-2006
Ervaring van Robert A. Medv in detail bekijken

Opleiding van Robert A. Medv

The Pennsylvania State University Undergraduate Degree
Sidney Kimmel Medical College Doctorate Degree

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Ervaring van Robert A. Medv in detail bekijken

Connecties

100 +

Eerstegraads connecties

10

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Persoonlijk netwerk weergeven

Verwante bedrijven

Beursgenoteerde bedrijven4
JOHNSON & JOHNSON

Health Technology

NEKTAR THERAPEUTICS

Health Technology

CARA THERAPEUTICS, INC.

Health Technology

ABBOTT INDIA LIMITED

Health Technology

Bedrijven in privébezit4

Health Technology

Health Services

Commercial Services

Commercial Services

Zie bedrijfsconnecties
  1. Beurs
  2. Insiders
  3. Robert A. Medv
-40 % Uitzonderlijk verlengd: onze abonnementen leiden je naar de beste beleggingen van morgen.
PROFITEER NU